Phase Ib/II study of Resolaris (ATYR-1940) in interstitial lung disease (ILD) patients
Phase of Trial: Phase I/II
Latest Information Update: 11 Jan 2016
At a glance
- Drugs ATYR 1940 (Primary)
- Indications Interstitial lung diseases
- Focus Adverse reactions; Therapeutic Use
- Sponsors aTyr Pharma
- 11 Jan 2016 The company will make a determination as to whether to move forward with this trial for Resolaris (by the end of 2016), according to an aTyr Pharma media release.
- 11 Jan 2016 Planned initiation date changed from 1 Jan 2016 to 1 Dec 2016, according to an aTyr Pharma media release.
- 20 Jun 2015 New trial record